ENZYCHEM LIFESCIENCES CORPORATION
Develops small molecule therapeutics for cancer, inflammation, and respiratory diseases.
183490 | KO
Overview
Corporate Details
- ISIN(s):
- KR7183490002
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 제천시 바이오밸리로 59, 제천시
- Website:
- https://www.enzychem.com/
- Sector:
- Manufacturing
Description
Enzychem Lifesciences Corporation is a biopharmaceutical company that develops novel small molecule therapeutics. The company's research targets fundamental pathways in inflammation to address significant unmet medical needs for patients with cancer, inflammatory diseases, and severe respiratory conditions. Its leading drug candidate, EC-18 (Mosedipimod), is a first-in-class oral small molecule derived from Sika deer antler. The clinical pipeline for EC-18 includes indications such as chemoradiation-induced oral mucositis (CRIOM), chemotherapy-induced neutropenia (CIN), acute radiation syndrome (ARS), and non-alcoholic steatohepatitis (NASH). The company also develops and manufactures Active Pharmaceutical Ingredients (APIs).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2020-08-14 00:00 |
반기보고서 (2020.06)
|
Korean | HTML • 2.0 MB | ||
| 2020-08-07 00:00 |
투자판단관련주요경영사항(신종 코로나바이러스 환자를 대상으로 폐렴에서 급성호흡부전 또는 급성호흡곤란증후군으로의 이향을 예방하는)
|
Korean | HTML • 15.6 KB | ||
| 2020-08-06 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | HTML • 197.6 KB | ||
| 2020-07-13 00:00 |
투자판단관련주요경영사항(신종 코로나바이러스로 인한 폐렴환자에서 EC-18의 안전성과 유효성을 평가하기 위한 다기관, 무작위배정, 이중맹검 FD…
|
Korean | HTML • 14.7 KB | ||
| 2020-06-25 00:00 |
기업설명회(IR)개최
|
Korean | HTML • 8.0 KB | ||
| 2020-06-22 00:00 |
주식매수선택권부여에관한신고
|
Korean | HTML • 12.8 KB | ||
| 2020-05-18 00:00 |
기업설명회(IR)개최
|
Korean | HTML • 7.5 KB | ||
| 2020-05-15 00:00 |
분기보고서 (2020.03)
|
Korean | HTML • 1.8 MB | ||
| 2020-05-12 00:00 |
투자판단관련주요경영사항(신종 코로나바이러스로 인한 폐렴환자에서 EC-18의 안전성과 유효성을 평가하기 위한 다기관, 무작위 배정, 이중 눈가림…
|
Korean | HTML • 14.6 KB | ||
| 2020-04-17 00:00 |
투자판단관련주요경영사항(신종 코로나바이러스 환자를 대상으로 폐렴에서 급성호흡부전 또는 급성호흡곤란증후군으로의 이행을 예방하는)
|
Korean | HTML • 11.7 KB | ||
| 2020-03-30 00:00 |
사업보고서 (2019.12)
|
Korean | HTML • 587.2 KB | ||
| 2020-03-24 00:00 |
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | HTML • 6.6 KB | ||
| 2020-03-24 00:00 |
정기주주총회결과
|
Korean | HTML • 29.2 KB | ||
| 2020-03-11 00:00 |
감사보고서제출
|
Korean | HTML • 27.6 KB | ||
| 2020-03-10 00:00 |
[기재정정]의결권대리행사권유참고서류
|
Korean | HTML • 1.1 MB |
Automate Your Workflow. Get a real-time feed of all ENZYCHEM LIFESCIENCES CORPORATION filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ENZYCHEM LIFESCIENCES CORPORATION
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ENZYCHEM LIFESCIENCES CORPORATION via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
